1644

hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. ER509322182US, in an envelope addressed ommissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the late shown below.

Dated: December 3, 2003

e: **X**X

au Harri

Docket No.: HO-PO

-P02046US1 (PATENII)

ECEIVE

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Marie-Claude Gingras, et al.

Application No.: 10/021,509

Application No.: 10/021,309

Filed: December 7, 2001

For: TREM-1 SPLICE VARIANT FOR USE AND

MODIFYING IMMUNE RESPONSES

Confirmation No.: 8559

Art Unit: 1644

Examiner: Michael Belyavskyi

## **RESPONSE TO RESTRICTION REQUIREMENT**

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In response to the restriction requirement set forth in the Office Action mailed November 5, 2003 (Paper No. 8), Applicant hereby provisionally elects claims Group I, Claims 1-17 for continued examination. In electing Group I, applicant also provisionally elects Infectious Disease as the species for continued examination.

Applicant believes no fee is due with this response. However, if a fee is due, please charge our Deposit Account No. 06-2375, under Order No. 10023489 from which the undersigned is authorized to draw.

Dated: December 3, 2003

Respectfully submitted,

Melissa W. Acosta

Registration No.: 45,872

FULBRIGHT & JAWORSKI L.L.P.

1301 McKinney, Suite 5100

Houston, Texas 77010-3095

(713) 651-5151

(713) 651-5246 (Fax)